Literature DB >> 18771809

Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.

Gert De Meerleer1, Valérie Fonteyne, Sabine Meersschout, Caroline Van den Broecke, Geert Villeirs, Nicolaas Lumen, Piet Ost, Katrien Vandecasteele, Wilfried De Neve.   

Abstract

INTRODUCTION: The aim was to prospectively evaluate both acute and late toxicity and biochemical non-evidence of disease (bNED) in patients treated with salvage intensity-modulated radiotherapy (IMRT) +/- androgen deprivation (AD) for biochemical relapse after radical prostatectomy (RP).
MATERIALS AND METHODS: IMRT was prescribed to a mean prescription dose to the planning target volume (PTV) of 75 Gy to be delivered in 37 fractions of 2 Gy. In total, 135 patients were treated with IMRT. Median age was 64 years. Median PSA level was 0.8 ng/ml. AD was initiated in 94 patients. Indications were perineural invasion, seminal vesicle invasion or Gleason score > or = 8 at RP. (1) Acute toxicity (n = 135). All patients were available for this analysis. Acute toxicity was scored using an in-house developed scoring system. (2) Late toxicity (n = 68). Only patients with a follow-up of at least 18 months were considered for late toxicity analysis. The RILIT score was used to register gastro-intestinal (GI) toxicity. An in-house developed scale was used to register genito-urinary (GU) toxicity. (3) bNED (n = 87). For bNED, all AD-naive patients (n = 38) together with the AD-positive patients with a follow-up > or = 18 months (n = 49) were considered. Factors influencing the results of salvage treatment were analyzed.
RESULTS: (1) Acute toxicity (n = 135). No patient developed grade 3 GI toxicity. We observed grade 2 toxicity in 20 patients. Four patients developed grade 3 GU toxicity. (2) Late toxicity (n = 68). One patient developed grade 3 rectal blood loss. One patient developed grade 3 anal pain (anal fissure). We observed grade 2 GI toxicity in 9 patients. Two patients developed grade 3GU toxicity. Twenty-one patients developed grade 2 GU toxicity. We observed an urethral stricture in 5 patients. (3) bNED (n = 87). The 3- and 5-year bNED was 67%. Gleason score at RP, perineural invasion and capsular perforation were significant predictors for bNED. PSA before IMRT (<1.0 vs. 1.0 ng/ml) showed a trend in predicting bNED (p = 0.08).
CONCLUSION: IMRT to 75Gy+/-AD can be delivered with low levels of acute and late toxicity. In patients without perineural invasion and capsular invasion and with a Gleason score > or = 7 (3 + 4), IMRT offers very good 5-years bNED.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771809     DOI: 10.1016/j.radonc.2008.07.027

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  19 in total

Review 1.  Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.

Authors:  Nitin Ohri; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter
Journal:  Eur J Cancer       Date:  2011-09-22       Impact factor: 9.162

2.  Volumetric image-guided highly conformal radiotherapy of the prostate bed: Toxicity analysis.

Authors:  Gianluca Ingrosso; Alessandra Carosi; Daniela di Cristino; Elisabetta Ponti; Andrea Lancia; Alessandra Murgia; Claudia Bruni; Pasquale Morelli; Franca Pietrasanta; Riccardo Santoni
Journal:  Rep Pract Oncol Radiother       Date:  2016-11-24

3.  Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.

Authors:  Richard Choo
Journal:  Cancer Res Treat       Date:  2010-03-31       Impact factor: 4.679

4.  Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.

Authors:  Michael Sia; George Rodrigues; Cynthia Menard; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Michael Milosevic; Padraig Warde; Charles Catton
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

5.  Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.

Authors:  Tim J Kruser; David F Jarrard; Andrew K Graf; Sean P Hedican; David R Paolone; John D Wegenke; Glenn Liu; Heather M Geye; Mark A Ritter
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

6.  Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy.

Authors:  Timothy N Showalter; Nitin Ohri; Kristopher G Teti; Kathleen A Foley; Scott W Keith; Edouard J Trabulsi; Costas D Lallas; Adam P Dicker; Jean Hoffman-Censits; Laura T Pizzi; Leonard G Gomella
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-24       Impact factor: 7.038

7.  Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors.

Authors:  Carsten Nieder; Kirsten Marienhagen; Roy M Kristensen; Torbjørn Sørbye; Lars Hoem
Journal:  Oncol Lett       Date:  2015-12-04       Impact factor: 2.967

8.  Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy.

Authors:  Natsuo Tomita; Takeshi Kodaira; Kazuhisa Furutani; Hiroyuki Tachibana; Rie Nakahara; Nobutaka Mizoguchi; Norio Hayashi
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-29       Impact factor: 4.553

9.  Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer.

Authors:  Felipe Couñago; Ana Aurora Díaz Gavela; Gemma Sancho; Irene Ortiz; Francisco José Marcos; Manuel Recio; Julio Fernández; Raquel Cano; Mar Jiménez; Israel J Thuissard; David Sanz-Rosa; Juan Castro Nováis; Eduardo Pardo; Yolanda Molina; Hugo Pérez García; Elia Del Cerro
Journal:  Rep Pract Oncol Radiother       Date:  2019-08-08

Review 10.  Salvage therapy for prostate cancer after radical prostatectomy.

Authors:  Nicholas G Zaorsky; Jeremie Calais; Stefano Fanti; Derya Tilki; Tanya Dorff; Daniel E Spratt; Amar U Kishan
Journal:  Nat Rev Urol       Date:  2021-08-06       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.